Shots:
- Sanofi has entered into an agreement to acquire Dynavax, incl. Heplisav-B (adult hepatitis B vaccine), Z-1018 (differentiated shingles vaccine candidate) & additional vaccine pipeline projects
- As per the deal, Sanofi will acquire Dynavax for $15.50/share in cash, representing the total equity value of ~$2.2B, after which a Sanofi subsidiary will merge with & into Dynavax following a successful tender offer; closing expected in Q1’26
- Heplisav-B is marketed in the US & differentiated by a two-dose, one-month regimen that delivers faster, high seroprotection vs three-dose, six-month hepatitis B vaccines, while Z-1018 is being evaluated in the P-I/II trial
Ref: Sanofi | Image: Sanofi | Press Release
Related News: Dren Bio and Sanofi Forge ~$1.8B Deal to Advance Next-Generation B-Cell Depletion Therapy
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
